Advertisement

Lymph Node Micrometastasis Prognosticates Survival for Patients with Stage 1 Bronchogenic Adenocarcinoma

  • Yijiu Ren
  • Liyan Zhang
  • Huikang Xie
  • Yunlang She
  • Hang Su
  • Dong Xie
  • Hui Zheng
  • Liping Zhang
  • Gening Jiang
  • Chunyan Wu
  • Chenyang Dai
  • Chang Chen
Thoracic Oncology
  • 27 Downloads

Abstract

Background

This study aimed to investigate the significance of lymph node micrometastasis (LNMM) in the lung cancer nodal categories.

Methods

Between 1 January 2009 and 31 December 2013, 589 patients with suspected c-stage 1 and p-T1-2aN0-1M0 lung adenocarcinoma were enrolled in this study. The study evaluated LNMM with cytokeratin (AE1/AE3) and transcription factor-1 (TTF1) (8G7G3/1) expression by immunohistochemistry. Recurrence-free survival (RFS) and overall survival (OS) were compared among the T1-2aN0-1M0 patients stratified by the new N categories.

Results

From 589 patients, 7892 removed lymph nodes were examined, and LNMM was observed in 55 (9.3%) of the patients. The patients without LNMM or N1 had the best RFS (5-year rate: 80% vs 25%; P < 0.001) and OS (5-year rate: 87% vs 43%; P < 0.001), followed by the patients with LNMM, compared with those in the N1 category (RFS: 5-year rate, 25% vs 8%; P = 0.010; OS: 5-year rate, 43% vs 20%; P = 0.009). Similarly, this trend was observed when patients were subdivided into the T1 and T2a categories. Multivariate analysis showed that the new N categories with the addition of LNMM were an independent prognostic factor. This result also was noticed in all subgroups.

Conclusions

The findings showed LNMM to be clinically significant as a risk factor for lung cancer. Clinicians should consider LNMM when estimating N categories to determine prognosis and the best treatment strategy.

Notes

Acknowledgment

This study was supported by the projects from the Shanghai Hospital Development Center (SHDC12015116), the Natural Science Foundation of Shanghai Minhang District (2016MHZ52), the Health and Family Planning Commission of Shanghai Municipality (2013ZYJB0003 and 20154Y0097), and the Shanghai Pujiang Program (15PJD034).

Disclosure

There are no conflicts of interest.

Supplementary material

10434_2018_6743_MOESM1_ESM.eps (544 kb)
Supplementary material 1 (EPS 544 kb)

References

  1. 1.
    Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4:568–77.CrossRefGoogle Scholar
  2. 2.
    Edwards T, Balata H, Elshafi M, et al. Adequacy of intraoperative nodal staging during surgical resection of NSCLC: influencing factors and its relationship to survival. J Thorac Oncol. 2017;12:1845–50.CrossRefPubMedCentralGoogle Scholar
  3. 3.
    Smeltzer MP, Faris NR, Ray MA, Osarogiagbon RU. Association of pathologic nodal staging quality with survival among patients with non-small cell lung cancer after resection with curative intent. JAMA Oncol. 2018;4:80–7.CrossRefGoogle Scholar
  4. 4.
    Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.CrossRefGoogle Scholar
  5. 5.
    Martin LW, D’Cunha J, Wang X, et al. Detection of occult micrometastases in patients with clinical stage 1 non-small-cell lung cancer: a prospective analysis of mature results of CALGB 9761 (Alliance). J Clin Oncol. 2016;34:1484–91.CrossRefPubMedCentralGoogle Scholar
  6. 6.
    Dai C, Xie H, Kadeer X, et al. Relationship of lymph node micrometastasis and micropapillary component and their joint influence on prognosis of patients with stage 1 lung adenocarcinoma. Am J Surg Pathol. 2017;41:1212–20.CrossRefPubMedCentralGoogle Scholar
  7. 7.
    Li J, Li ZN, Yu LC, et al. Gene diagnosis of micrometastases in regional lymph nodes of patients with stage 1 non-small cell lung cancer: impact on staging and prognosis. Clin Transl Oncol. 2013;15:882–8.CrossRefPubMedCentralGoogle Scholar
  8. 8.
    Deng XF, Jiang L, Liu QX, et al. Lymph node micrometastases are associated with disease recurrence and poor survival for early-stage non-small cell lung cancer patients: a meta-analysis. J Cardiothorac Surg. 2016;11:28.CrossRefPubMedCentralGoogle Scholar
  9. 9.
    Rusch VW, Hawes D, Decker PA, et al. Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial. J Clin Oncol. 2011;29:4313–9.CrossRefPubMedCentralGoogle Scholar
  10. 10.
    Giuliano AE, Connolly JL, Edge SB, et al. Breast cancer: major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:290–303.CrossRefPubMedCentralGoogle Scholar
  11. 11.
    Asamura H, Chansky K, Crowley J, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung cancer. J Thorac Oncol. 2015;10:1675–84.CrossRefPubMedCentralGoogle Scholar
  12. 12.
    Wood DE, Kazerooni EA, Baum SL, et al. Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2018;16:412–41.CrossRefGoogle Scholar
  13. 13.
    Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: International Multidisciplinary Classification of Lung Adenocarcinoma. Proc Am Thorac Soc. 2011;8:381–5.CrossRefPubMedCentralGoogle Scholar
  14. 14.
    Liu H, Ye YK, Li GM, et al. Diagnosis of lymph node micrometastasis at the pN(0) stage of lung adenocarcinoma using a combination of markers. GMR Genet Mol Res. 2014;13:5594–600.CrossRefPubMedCentralGoogle Scholar
  15. 15.
    Dai C, Shen J, Ren Y, et al. Choice of surgical procedure for patients with non-small-cell lung cancer ≤ 1 cm or > 1 to 2 cm among lobectomy, segmentectomy, and wedge resection: a population-based study. J Clin Oncol. 2016;34:3175–82.CrossRefPubMedCentralGoogle Scholar
  16. 16.
    Turner RR, Weaver DL, Cserni G, et al. Nodal stage classification for breast carcinoma: improving interobserver reproducibility through standardized histologic criteria and image-based training. J Clin Oncol. 2008;26:258–63.CrossRefPubMedCentralGoogle Scholar
  17. 17.
    Andersson Y, Frisell J, Sylvan M, de Boniface J, Bergkvist L. Breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes. J Clin Oncol. 2010;28:2868–73.CrossRefPubMedCentralGoogle Scholar
  18. 18.
    . Sloothaak DA, Sahami S, van der Zaag-Loonen HJ, et al. The prognostic value of micrometastases and isolated tumour cells in histologically negative lymph nodes of patients with colorectal cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2014;40:263–9.CrossRefPubMedCentralGoogle Scholar
  19. 19.
    Lee CM, Cho JM, Jang YJ, et al. Should lymph node micrometastasis be considered in node staging for gastric cancer? The significance of lymph node micrometastasis in gastric cancer. Ann Surg Oncol. 2015;22:765–71.CrossRefPubMedCentralGoogle Scholar
  20. 20.
    Ueno S, Tanabe G, Sako K, et al. Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology. 2001;34:529–34.CrossRefPubMedCentralGoogle Scholar
  21. 21.
    Cserni G. Metastases in axillary sentinel lymph nodes in breast cancer as detected by intensive histopathological work up. J Clin Pathol. 1999;52:922–4.CrossRefPubMedCentralGoogle Scholar
  22. 22.
    Weaver DL, Krag DN, Manna E, Ashikaga T, Harlow SP, Bauer KD. Comparison of pathologist-detected and automated computer-assisted image analysis detected sentinel lymph node micrometastases in breast cancer. Mod Pathol. 2003;16(11):1159–63.CrossRefPubMedCentralGoogle Scholar
  23. 23.
    Weaver DL, Le UP, Dupuis SL, et al. Metastasis detection in sentinel lymph nodes: comparison of a limited widely spaced (NSABP protocol B-32) and a comprehensive narrowly spaced paraffin block sectioning strategy. Am J Surg Pathol. 2009;33:1583–9.CrossRefPubMedCentralGoogle Scholar
  24. 24.
    Weaver DL. Pathology evaluation of sentinel lymph nodes in breast cancer: protocol recommendations and rationale. Mod Pathol. 2010;23(Suppl 2):S26–32.CrossRefGoogle Scholar
  25. 25.
    Weaver DL. Pathological evaluation of sentinel lymph nodes in breast cancer: a practical academic perspective from America. Histopathology. 2005;46:702–6.CrossRefPubMedCentralGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Yijiu Ren
    • 1
  • Liyan Zhang
    • 2
  • Huikang Xie
    • 3
  • Yunlang She
    • 1
  • Hang Su
    • 1
  • Dong Xie
    • 1
  • Hui Zheng
    • 1
  • Liping Zhang
    • 3
  • Gening Jiang
    • 1
  • Chunyan Wu
    • 3
  • Chenyang Dai
    • 1
  • Chang Chen
    • 1
  1. 1.Department of Thoracic Surgery, Shanghai Pulmonary HospitalTongji University School of MedicineShanghaiPeople’s Republic of China
  2. 2.Department of Respiratory Medicine, South Campus, Renji Hospital, School of MedicineShanghai Jiaotong UniversityShanghaiPeople’s Republic of China
  3. 3.Department of Pathology, Shanghai Pulmonary HospitalTongji University School of MedicineShanghaiPeople’s Republic of China

Personalised recommendations